Effects of culture conditions on N‐glycolylneuraminic acid (Neu5Gc) content of a recombinant fusion protein produced in CHO cells
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
CHO cells express glycoproteins containing both the N‐acetylneuraminic acid (Neu5Ac) and minor amounts of the N‐glycolylneuraminic acid (Neu5Gc) forms of sialic acid. As Neu5Gc is not expressed in humans and can be recognized as a foreign epitope, there is the potential for immunogenicity issues for glycoprotein therapeutics. During process development of a glycosylated fusion protein expressed by CHO cells, a number of culture conditions were identified that affected the Neu5Gc content of the recombinant glycoprotein. Sodium butyrate (SB), a well‐known additive reported to enhance recombinant protein productivity in specific cases, minimally affected product titers here, but did decrease Neu5Gc levels by 50–62%. A shift in culture temperature to a lower value after the exponential growth phase was used to extend the culture period. It was found that the Neu5Gc levels were 59% lower when the temperature shift occurred later near the stationary phase of the culture compared to an early‐temperature shift, near the end of the exponential growth phase. Studies on the effects of pCO 2 with this product showed that the Neu5Gc levels were 46% lower at high pCO 2 conditions (140 mmHg) compared to moderate pCO 2 levels (20–80 mmHg). Finally, a comparison of sodium carbonate versus sodium hydroxide as the base used for pH control resulted in a reproducible 33% decrease in Neu5Gc in bioreactors using sodium hydroxide. These results are of practical importance as SB is a commonly tested additive, and the other factors affecting Neu5Gc can conveniently be used to reduce or control Neu5Gc in processes for the manufacture of glycoprotein therapeutics. Biotechnol. Bioeng. 2010;105: 1048–1057. © 2009 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid
Tangvoranuntakul, P., Gagneux, P., Diaz, S., Bardor, M., Varki, N., Varki, A., & Muchmore, E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2131556100 · Cited by 625
Zhu, M. M., Goyal, A., Rank, D. L., Gupta, S. K., Boom, T. V., & Lee, S. S. (2008) · Biotechnology Progress · doi:10.1021/bp049815s · Cited by 199 · cited 2×
“The high pCO2 level of 140mmHg was chosen to be consistent with that previously reported for this process in 5,000-L bioreactors (Zhu et al., 2005).”
MethodResultMetabolic control of recombinant protein N‐glycan processing in NS0 and CHO cells
Baker, K. N., Rendall, M. H., Hills, A. E., Hoare, M., Freedman, R. B., & James, D. C. (2001) · Biotechnology and Bioengineering · doi:10.1002/bit.1051 · Cited by 184 · cited 3×
“…(Chenu et al., 2003), and there are reports of Neu5Gc being affected by environmental conditions such as high pCO2 (Kimura and Miller, 1997), manipulation of nucleotide-sugar levels by feeding N-acetylmannosamine (Baker et al. 2001), and by HEPES buffer and high pH (Muthing et al., 2003).”
BackgroundSung, Y. H., Song, Y. J., Lim, S. W., Chung, J. Y., & Lee, G. M. (2004) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2004.05.003 · Cited by 92
Xing, Z., Li, Z., Chow, V., & Lee, S. S. (2008) · Biotechnology Progress · doi:10.1021/bp070466m · Cited by 52 · cited 5×
“Osmolality remained within normal ranges and well below the toxicity threshold limit of 382mOsm/kg (Xing et al., 2008).”
BackgroundMethodInfluentialSelf-citation
Cited by
Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars
Berkowitz, S. A., Engen, J. R., Mazzeo, J. R., & Jones, G. B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3746 · Cited by 529
Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins
Ghaderi, D., Taylor, R. E., Padler-Karavani, V., Diaz, S., & Varki, A. (2010) · Nature Biotechnology · doi:10.1038/nbt.1651 · Cited by 372
“Especially in light of trends toward administering increasingly higher amounts of certain biotherapeutics over longer periods of time, some biopharmaceutical companies are exploring steps to reduce levels of Neu5Gc in their product”
Ghaderi, D., Zhang, M., Hurtado-Ziola, N., & Varki, A. (2012) · Biotechnology and Genetic Engineering Reviews · doi:10.5661/bger-28-147 · Cited by 320
“For instance, sodium butyrate, a cell culture additive in the pharmaceutical industry is capable of decreasing Neu5Gc levels in CHO cells by 50-62% (Borys et al., 2009).”
BackgroundInfluentialFc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics
Rath, T., Baker, K., Dumont, J. A., Peters, R. T., Jiang, H., Qiao, S.-W., Lencer, W. I., Pierce, G. F., & Blumberg, R. S. (2015) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2013.834293 · Cited by 281
High-density mammalian cell cultures in stirred-tank bioreactor without external pH control
Xu, S., & Chen, H. (2016) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2016.06.019 · Cited by 99
“Maintaining a desired pCO2 level constantly could be beneficial for processes with product quality sensitive to the pCO2 levels (Borys et al., 2010; Eisenkraetzer et al., 2013).”
BackgroundHa, T. K., Kim, D., Kim, C. L., Grav, L. M., & Lee, G. M. (2022) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107831 · Cited by 74
Traylor, M. J., Bernhardt, P., Tangarone, B. S., & Varghese, J. (2018) · Biopharmaceutical Processing · doi:10.1016/b978-0-08-100623-8.00047-5 · Cited by 1
Metadata
- Authors
- Borys, M. C., Dalal, N. G., Abu‐Absi, N. R., Khattak, S. F., Jing, Y., Xing, Z., & Li, Z. J.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2010-01-27
- Volume
- 105
- Issue
- 6
- Pages
- 1048-1057
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2120089299
- Cited by
- 83
- References
- 6
- FWCI
- 1.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.